ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) jumped as much as 11.8 percent after the stock received an encouraging view from Mizuho Financial Group. The stock was initiated with a buy recommendation and price target of $11. Mizuho’s price target implies potential upside of 127 percent from the stock’s closing price on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares after opening at $5.47 moved to $5.50 on last trade day and at the end of the day closed at $5.17. Company price to sales ratio in past twelve months was calculated as 611.48 and price to cash ratio as 7.17. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) showed a positive weekly performance of 16.70%.
Shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) jumped significantly Thursday after the cancer drug developer announced encouraging interim results for its drug candidate. Presenting at a European breast cancer event, the company painted rosy picture of the progress in its experimental breast cancer therapy. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares fell -4.04% in last trading session and ended the day on $4.99. SNTA return on equity ratio is recorded as -231.70% and its return on assets is -112.90%.Synta Pharmaceuticals Corp. (NASDAQ:SNTA) yearly performance is -40.02%.
ChemoCentryx (NASDAQ:CCXI) CEO Thomas J. Schall unloaded 20,000 shares of ChemoCentryx stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $7.25, for a total value of $145,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,148,707 shares in the company, valued at approximately $15,578,126. ChemoCentryx Inc (NASDAQ:CCXI) shares moved down -5.67% in last trading session and was closed at $7.65, while trading in range of $7.62-$8.15.ChemoCentryx Inc (NASDAQ:CCX) year to date performance is 32.12%.
Robert W. Baird started coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research report sent to investors on Monday morning, AnalystRatings.Net reports. The firm issued a neutral rating and a $41.00 price target on the stock. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) weekly performance is 4.85%. On last trading day company shares ended up $36.98. {Full Company Name} distance from 50-day simple moving average is -2.40%. Analysts mean target price for the company is $47.33.